Reuters -- Myriad Genetics Inc lowered its total molecular diagnostic revenue forecast for fiscal 2009, citing patients delaying or cancelling doctor visits due to the recession, sending its shares down 21 percent.
Reuters -- Myriad Genetics Inc lowered its total molecular diagnostic revenue forecast for fiscal 2009, citing patients delaying or cancelling doctor visits due to the recession, sending its shares down 21 percent.
